EUnetHTA 21 shares draft on medicinal JCA timelines in D5.4 deliverable

By HEOR Staff Writer

July 4, 2023

The objective is to produce Joint Clinical Assessments (JCA) for medicinal products and medical devices in order to improve quality, consistency, and national adoption of the JCA. The production process will be standardized. During the production, the methodological convergence paths defined in EUnetHTA JA3 will be tested, including the PICO concept paper and the GRADE framework paper. Additionally, the new methodological guidelines developed by EUnetHTA 21, as well as revised templates and guidelines, will be tested to address challenges identified in EUnetHTA JA3.

 

Read the draft document here: on the link below

Join the discussion on July 13th, 2023. Register now via Eventbrite at https://www.eventbrite.co.uk/e/eunethta-21-htd-meeting-tickets-647889433737?aff=oddtdtcreator 

Reference url

Recent Posts

Weight Loss: Advances in Hormone-Based Obesity Treatments

By HEOR Staff Writer

November 12, 2025

Advances in Hormone-Based Pharmacotherapies for Obesity Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges

By HEOR Staff Writer

NICE's Unified Prioritization Roadmap NICE NHS prioritization has led to a new, unified framework and board that will tackle emerging healthcare innovations while managing finite assessment capacity. The approach focuses on high-impact areas, including mental health, early cancer detect...
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for s...